KC2 tumours showed significantly reduced levels of P16INK4A and increased levels of c‐MYC, consistent with their high proliferative capacity and aggressive clinical behaviour (Table S5 and Figure S6E). This evidence concerns the gene CDKN2A and neoplasm.